A theme involving higher costs to expand contract manufacturing capacity for nucleic acid drugs and the resulting pressure on profits from pricing adjustments for certain projects. It covers the impact on earnings of costs associated with expanding contract manufacturing capacity and project-specific pricing adjustments.